Harmony Biosciences reported Q3 WACIX net revenue of $269 million and reiterated 2026 guidance of $1 to $1.04 billion. BP-205 showed an approximately 29-hour effective half-life, and Peter Anastasiou will become CEO on January 1, 2027.
HRMY · Harmony Biosciences Holdings, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Harmony’s net product revenue increased $29.5 million, or 12.3%, for the three months ended September 30, 2026. Pitolisant GR received full FDA review with a target PDUFA date of April 1, 2027.
Harmony Biosciences reported WAKIX net revenue of $268.9 million for the quarter ended September 30, 2026 and reiterated 2026 guidance of $1.0 billion to $1.04 billion. BP-205 preliminary results were favorable, and Peter Anastasiou will become CEO on January 1, 2027.
Harmony Biosciences Holdings, Inc. said Jeffrey M. Dayno will retire as CEO effective December 31, 2026, receive $770,000, and be succeeded by Peter Anastasiou effective January 1, 2027. Anastasiou’s salary will be $725,000, with equity awards of $1,750,000 and $750,000.
Harmony Biosciences Holdings, Inc. appointed Peter Anastasiou CEO and director effective January 1, 2027; Jeffrey M. Dayno, M.D., will retire and leave the board on December 31, 2026. Full-year 2026 WAKIX net revenue guidance remains $1.0 billion to $1.04 billion.